Xcout Intel
Poxel competitors & alternatives
The 12 closest competitors and alternatives to Poxel among pharmaceuticals companies — ranked by similarity to what Poxel actually does, not by market-cap band.
Subscribe to see Poxel’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Poxel
Poxel S.A. is a biopharmaceutical firm in the clinical development phase, dedicated to discovering innovative therapies for metabolic disorders, particularly type 2 diabetes and various liver conditions. Its primary asset, TWYMEEG (Imeglimin), is an oral medication that addresses mitochondrial dysfunction and has already received approval in Japan for managing type 2 diabetes. Poxel is also advancing PXL770, an activator of the adenosine monophosphate-activated protein kinase (AMPK) enzyme, currently in Phase 2a trials for various chronic metabolic diseases, notably liver ailments like non-alcoholic steatohepatitis (NASH). Furthermore, the company holds licensing agreements: one with Enyo Pharma S.A.S. for a farnesoid X receptor (FXR) agonist, now in a Phase 2a study for hepatitis B and NASH, and another with DeuteRx LLC for PXL065, a mitochondrial pyruvate carrier inhibitor undergoing Phase 1 evaluation specifically for NASH treatment. Established in 2009, Poxel S.A. operates from its headquarters in Lyon, France.
Poxel at a glance
Poxel is a pharmaceuticals company headquartered in France. It is publicly listed (0RA2) with a market capitalisation of $22.7M. Xcout tracks 4 named people at Poxel, including Yves Decadt (Chief Executive Officer).
Poxel leadership
- Yves DecadtChief Executive Officer
- Alexandre BragadirSenior Investment Director
- Amit KohliIndependent Director
- Sophie Jacq LapointeIndependent Director
Top 12 Poxel competitors
Ranked by semantic similarity — how close each company is to Poxel by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals company
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Similar pharmaceuticals company
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Similar pharmaceuticals company
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Pharmaceuticals, Biotechnology & Life Sciences
Dimerix Limited is an Australian biopharmaceutical firm dedicated to discovering and bringing to market innovative pharmaceutical solutions for medical conditions where existing treatments are insufficient. The company's leading therapeutic candidate, DMX-200, is currently undergoing extensive clinical evaluation, including two separate Phase 3 trials targeting respiratory complications linked to COVID-19. DMX-200 is also in a distinct Phase 3 clinical trial for focal segmental glomerulosclerosis (FSGS), a severe kidney disorder, and is being developed for the treatment of diabetic kidney disease. Additionally, Dimerix is advancing DMX-700, which is intended for chronic obstructive pulmonary disease (COPD). The company's corporate headquarters are located in Fitzroy, Australia.
Similar pharmaceuticals company
Agios Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of treatments within cellular metabolism and associated biological domains. Its lead product, PYRUKYND (mitapivat), serves as an activator for both healthy and various mutated forms of the pyruvate kinase (PK) enzyme, targeting the management of hemolytic anemias. Additionally, AG-946, an investigational compound, is currently undergoing Phase I clinical evaluation for hemolytic anemias and other conditions. Established in 2007, Agios Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
Similar pharmaceuticals company
Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical enterprise, primarily involved in the procurement, advancement, and commercialization of prescription medications. Its strategic focus areas include acute hospital care, gastroenterology, rheumatology, and oncology, with operations spanning both the United States and global markets. The company's existing product line includes: Acetadote: an injectable solution for treating acetaminophen poisoning. Caldolor: an injectable medication for managing pain and fever. Kristalose: a prescription oral laxative solution effective for chronic and acute constipation. Omeclamox-Pak: used in the treatment of Helicobacter pylori infection and duodenal ulcer disease. Vaprisol: an injectable therapy for euvolemic and hypervolemic hyponatremia. Vibativ: an injectable antibiotic prescribed for severe bacterial infections, including those acquired in hospitals or associated with ventilators, as well as complex skin and skin structure infections. In its development pipeline, Cumberland is advancing: RediTrex injection: designed to treat active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, along with disabling psoriasis. Ifetroban: a product candidate currently in Phase II clinical trials for aspirin-exacerbated respiratory disease, systemic sclerosis, and Duchenne muscular dystrophy. It has also completed Phase II clinical trials for hepatorenal syndrome and portal hypertension, with further clinical investigation ongoing for its potential use in progressive fibrosing interstitial lung diseases. An additional product candidate in Phase II clinical trials, aimed at reducing cholesterol levels for hospital use. Founded in 1999, the company's corporate headquarters are located in Nashville, Tennessee.
Similar pharmaceuticals company
SCOHIA PHARMA, Inc. is a clinical-stage specialty bioventure headquartered in Fujisawa, Japan. Established in 2017, the company focuses its research and development on lifestyle-related diseases including cardiovascular, metabolic, and renal disorders.
Similar pharmaceuticals company
Shionogi & Co., Ltd. is a Japanese enterprise focused on the entire lifecycle of pharmaceutical products, diagnostic tools, and medical equipment, encompassing their investigation, creation, production, and supply within Japan. The company's marketed portfolio includes Fetroja, a therapy for multidrug-resistant gram-negative bacterial infections; Xofluza, an antiviral medication targeting influenza; and Tivicay, which is used in HIV management. Shionogi actively pursues the development of numerous compounds addressing a wide array of medical conditions. Its investigational pipeline features treatments for opioid-induced constipation (Symproic); inflammatory pain (S-120083); neuropathic pain (S-010887, sivopixant, and S-637880 for low back pain); insomnia (S-117957); and central nervous system disorders such as sleep apnea syndrome, refractory/unexplained chronic cough (both sivopixant), depression (Zuranolone), and attention-deficit/hyperactivity disorder (SDT-001). The company also has candidates for Fragile X syndrome and Alzheimer's disease (BPN14770), as well as obesity (S-237648, S-309309). Its robust research pipeline further extends to treatments for conditions including decompensated liver cirrhosis (ADR-001) and NASH (S-723595). In oncology, Shionogi is advancing S-588410 for esophageal and bladder cancers, S-488210 for head and neck squamous cell carcinoma, and S-588210, S-222611, and S-531011 for various solid tumors and malignancies. Other investigational therapies include S-770108 for idiopathic pulmonary fibrosis, SR-0379 for cutaneous ulcers, S-005151 for stroke and epidermolysis bullosa, and S-0373 for spinocerebellar ataxia. The company is also heavily invested in COVID-19 therapeutics, with S-600918, S-217622, and S-555739 aimed at treating the virus and managing its worsening effects. Additionally, Shionogi provides diagnostic antibody test kits specifically for COVID-19. Shionogi & Co., Ltd. collaborates with academic and research institutions like Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University on joint initiatives, particularly in the development of antimalarial medications. Founded in Osaka, Japan, in 1878, the organization initially operated under the name Shionogi Shoten Co., Ltd. before adopting its current corporate identity, Shionogi & Co., Ltd., in 1943.
Similar pharmaceuticals company
Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are focused on addressing significant unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and a spectrum of rare or orphan brain cancers. The company's primary drug candidate, Tolimidone, a selective activator of the lyn kinase enzyme, is currently undergoing Phase II clinical trials for the management of Type 1 diabetes. Additionally, Biodexa is progressing MTX110 through Phase I studies as an investigational treatment targeting specific challenging brain malignancies such as diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. Beyond its direct drug pipeline, Biodexa Pharmaceuticals also provides a suite of advanced drug delivery platforms designed to optimize therapeutic efficacy. These include Q-Sphera, a microtechnology utilizing polymer microspheres for controlled, sustained release of medications; MidaSolve, an oligosaccharide nanotechnology that facilitates the solubilization of drugs, enabling their direct and localized administration into tumor sites; and MidaCore, which employs gold nanoparticles for precise targeting of diseased areas, allowing for the delivery of either chemotherapeutic or immunotherapeutic agents. The company has established strategic collaboration agreements with pharmaceutical industry leaders Janssen and Melior.
Similar pharmaceuticals company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the exploration, advancement, and marketing of innovative therapies rooted in RNA interference (RNAi) technology. The company's research pipeline for RNAi treatments targets a diverse array of medical conditions, encompassing inherited disorders, cardiovascular and metabolic diseases, hepatic infections, and illnesses affecting the central nervous system (CNS) and eyes. Alnylam's commercialized products include ONPATTRO (patisiran), an injectable lipid complex prescribed for adults experiencing polyneuropathy due to hereditary transthyretin-mediated amyloidosis. Also marketed are GIVLAARI, used to treat acute hepatic porphyria (AHP) in adult patients, and OXLUMO (lumasiran), indicated for primary hyperoxaluria type 1 (PH1). In terms of its developmental programs, the company is progressing several candidates: Givosiran, for the treatment of AHP in adolescent patients. Patisiran, being investigated for transthyretin amyloidosis (ATTR amyloidosis) when accompanied by cardiomyopathy. Cemdisiran, aimed at complement-mediated diseases. ALN-AAT02, for liver disease associated with AAT deficiency. ALN-HBV02, targeting chronic hepatitis B virus infection. Zilebesiran, for the management of hypertension. ALN-HSD, for non-alcoholic steatohepatitis (NASH). Fitusiran, addressing hemophilia and various rare bleeding disorders. Inclisiran, developed to treat hypercholesterolemia. Lumasiran, for advanced PH1 and recurrent kidney stones. Vutrisiran, currently in Phase 3 clinical trials for ATTR amyloidosis. Alnylam Pharmaceuticals maintains strategic alliances with several key players in the industry. It collaborates with Regeneron Pharmaceuticals, Inc. on the discovery, development, and commercialization of RNAi therapeutics for ocular and CNS targets. Another significant partnership exists with Sanofi Genzyme, focusing on the broader development and commercialization of RNAi treatments. Furthermore, the company holds licensing and collaboration agreements with Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. The company was established in 2002 and operates from its headquarters in Cambridge, Massachusetts.
Similar pharmaceuticals company
Thiogenesis Therapeutics is a clinical-stage biotechnology company that develops novel cysteamine-based thiol compounds to treat inherited and acquired mitochondrial diseases, metabolic conditions, and rare pediatric disorders. Its lead candidate, TTI-0102, is designed to reduce oxidative stress, restore cellular redox balance, and improve upon the tolerability and dosing limitations of legacy therapies for conditions such as cystinosis and Leigh syndrome.
Similar pharmaceuticals company
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Poxel and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Poxeland every competitor above — in one live dashboard.
Subscribe to Xcout Intel →